Use of Ribosome-Inactivating Proteins from Sambucus for the？Construction of Immunotoxins and Conjugates for Cancer？Therapy 英文参考文献.docVIP

Toxins 2011, 3, 420-441; doi:10.3390/toxins3050420 OPEN ACCESS toxins ISSN 2072-6651 /journal/toxins Review Use of Ribosome-Inactivating Proteins from Sambucus for the Construction of Immunotoxins and Conjugates for Cancer Therapy José M. Ferreras 1,*, Lucía Citores 1, Rosario Iglesias 1, Pilar Jiménez 2 and Tomás Girbés 2 1 Department of Biochemistry, Molecular Biology and Physiology, Faculty of Sciences, University of Valladolid, E-47005 Valladolid, Spain; E-Mails: luciac@bio.uva.es (L.C.); riglesia@bio.uva.es (R.I.) 2 Nutrition and Bromatology, Faculty of Medicine, E-47005 Valladolid, Spain; E-Mails: pilarj@bio.uva.es (P.J.); girbes@bio.uva.es (T.G.) * Author to whom correspondence should be addressed; E-Mail: rosario@bio.uva.es; Tel.: +34-983-423-083; Fax: +34-983-423-083. Received: 28 February 2011; in revised form: 2 April 2011 / Accepted: 25 April 2011 / Published: 29 April 2011 Abstract: The type 2 ribosome-inactivating proteins (RIPs) isolated from some species belonging to the Sambucus genus, have the characteristic that although being even more active than ricin inhibiting protein synthesis in cell-free extracts, they lack the high toxicity of ricin and related type 2 RIPs to intact cells and animals. This is due to the fact that after internalization, they follow a different intracellular pathway that does not allow them to reach the cytosolic ribosomes. The lack of toxicity of type 2 RIPs from Sambucus make them good candidates as toxic moieties in the construction of immunotoxins and conjugates directed against specific targets. Up to now they have been conjugated with either transferrin or anti-CD105 to target either transferrin receptor- or endoglin-overexpressing cells, respectively. Keywords: ribosome-inactivating proteins; Sambucus; immunotoxin; endoglin (CD105); transferrin  Toxins 2011, 3 421 1. Introduction Ribosome-inactivating proteins (R